# Phase 3 depression trials recruiting: 24 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 24 trials in phase 3 for depression that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 depression trials: 24 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/depression

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 24
- Recruiting or not yet: 24
- Read on: November 19, 2026

## Trials

The 24 newest of 24, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 16, 2026 | NCT07822321 | Brexanolone Lifting Outcomes Of Moms | Lipocine Inc. | Phase 3 | Recruiting | Depression, Postpartum, Postpartum Depression (PPD), Post-partum Depression, Postnatal Depression, Post-Natal... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07822321) |
| August 20, 2026 | NCT07775300 | A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder | Eli Lilly and Company | Phase 3 | Recruiting | Depressive Disorder, Major | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07775300) |
| July 23, 2026 | NCT07721961 | A Study of MI078 for Postpartum Depression | Nanjing Minova Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Postpartum Depression (PPD) | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07721961) |
| June 3, 2026 | NCT07623135 | Lumateperone for Late-Life Depression | Sponsor not shown (see the record) | Phase 3 | Recruiting | Treatment Resistant Depression (TRD), Late Life Depression (LLD), Depression / Major Depressive Disorder | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623135) |
| March 11, 2026 | NCT07464886 | Prefrontal Glutamatergic Modulation by NAC and MBCT for Depression in Youth | University of Cincinnati | Phase 3 | Recruiting | Mild Depression | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07464886) |
| February 17, 2026 | NCT07412756 | A Study of Brenipatide in Adult Participants With Major Depressive Disorder | Eli Lilly and Company | Phase 3 | Recruiting | Depressive Disorder, Major | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07412756) |
| December 12, 2025 | NCT07280065 | REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool | Senseye, Inc. | Phase 3 | Recruiting | PTSD - Post Traumatic Stress Disorder | 1,900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07280065) |
| November 10, 2025 | NCT07226232 | Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression | VA Office of Research and Development | Phase 3 | Recruiting | Major Depression | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07226232) |
| July 28, 2025 | NCT07088380 | Ketamine Augmentation of ECT in Treatment-Resistant Depression | Università Vita-Salute San Raffaele | Phase 3 | Recruiting | Major Depressive Disorder, Treatment Resistant Depression | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07088380) |
| May 11, 2025 | NCT06966401 | Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive... | Neurocrine Biosciences | Phase 3 | Recruiting | Major Depressive Disorder | 850 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06966401) |
| May 8, 2025 | NCT06963021 | NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major... | Neurocrine Biosciences | Phase 3 | Recruiting | Major Depressive Disorder | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06963021) |
| April 4, 2025 | NCT06911112 | NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major... | Neurocrine Biosciences | Phase 3 | Recruiting | Major Depressive Disorder | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06911112) |
| February 19, 2025 | NCT06835504 | Morphine or Ketamine for Analgesia | Columbia University | Phase 3 | Recruiting | Abdominal Pain, Isolated Extremity Fracture, Pain, Pediatrics | 1,010 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06835504) |
| January 27, 2025 | NCT06793397 | A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder | Cybin IRL Limited | Phase 3 | Recruiting | Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders... | 330 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06793397) |
| January 22, 2025 | NCT06786624 | Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Neurocrine Biosciences | Phase 3 | Recruiting | Major Depressive Disorder | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06786624) |
| January 17, 2025 | NCT06781697 | InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression | Sunnybrook Health Sciences Centre | Phase 3 | Recruiting | Treatment Resistant Depression | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06781697) |
| December 31, 2024 | NCT06752759 | Nebulized Ketamine for the Treatment of Major Depressive Disorder | Sponsor not shown (see the record) | Phase 3 | Recruiting | Severe Depression, Moderate Depression, Ketamine, Midazolam, Peripheral Nervous System Agents, Central Nervous System... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06752759) |
| December 27, 2024 | NCT06748222 | E-Mindfulness Approaches for Living After Breast Cancer | NRG Oncology | Phase 3 | Recruiting | Breast Cancer, Depression | 402 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06748222) |
| December 3, 2024 | NCT06713616 | PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study | Yale University | Phase 3 | Recruiting | Depression | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06713616) |
| July 18, 2024 | NCT06508710 | Early Effects of Ketamine vs Placebo With Venlafaxine in Severe Depression Patients | Assistance Publique - Hôpitaux de Paris | Phase 3 | Recruiting | Major Depressive Episode | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06508710) |
| May 22, 2023 | NCT05867849 | Cannabidiol for Bipolar Depression (CBD-BD) | University of British Columbia | Phase 3 | Recruiting | Bipolar Disorder | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05867849) |
| March 2, 2021 | NCT04777357 | A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric... | AbbVie | Phase 3 | Recruiting | Depression, Bipolar I Disorder | 338 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04777357) |
| August 24, 2018 | NCT03646058 | Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode | Centre Hospitalier Universitaire de Nīmes | Phase 3 | Recruiting | Suicidal Ideation, Major Depressive Episode | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03646058) |
| October 6, 2015 | NCT02568878 | Creatine for Depressed Male and Female Methamphetamine Users | Montana State University | Phase 3 | Recruiting | Depression, Anxiety, Methamphetamine Dependence | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02568878) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Neurocrine Biosciences](https://specstream.ai/data/clinical-trials/company/neurocrine-biosciences) | 4 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 2 |
| NRG Oncology | 1 |
| Lipocine Inc. | 1 |
| Nanjing Minova Pharmaceutical Co., Ltd. | 1 |
| Cybin IRL Limited | 1 |
| Senseye, Inc. | 1 |
| Montana State University | 1 |
| University of Cincinnati | 1 |
| Centre Hospitalier Universitaire de Nīmes | 1 |
| University of British Columbia | 1 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 1 |
| Università Vita-Salute San Raffaele | 1 |
| Yale University | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Columbia University | 1 |
| Sunnybrook Health Sciences Centre | 1 |
| VA Office of Research and Development | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 18 |
| Canada | 6 |
| Australia | 5 |
| United Kingdom | 5 |
| Puerto Rico | 4 |
| Poland | 4 |
| China | 3 |
| Germany | 3 |
| Greece | 3 |
| South Korea | 3 |
| Spain | 3 |
| Taiwan | 3 |
| Czechia | 2 |
| Belgium | 2 |
| Bulgaria | 2 |
| Finland | 2 |
| Hungary | 2 |
| Italy | 2 |
| Latvia | 2 |
| Lithuania | 2 |
| Romania | 2 |
| Slovakia | 2 |
| France | 2 |
| Brazil | 2 |
| Japan | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Private equity firms in the United States](https://specstream.ai/data/businesses/private-equity-firms/united-states)
- [Demolition contractors in the United States](https://specstream.ai/data/businesses/demolition-contractors/united-states)
- [Rheumatology practices in the United States](https://specstream.ai/data/businesses/rheumatology-practices/united-states)
- [Elevator companies in the United States](https://specstream.ai/data/businesses/elevator-companies/united-states)
- [Specialty schools in the United States](https://specstream.ai/data/businesses/specialty-schools/united-states)
- [Fingerprinting services in the United States](https://specstream.ai/data/businesses/fingerprinting-services/united-states)
